Gorai I, Uemura T, Mizuguchi H
Jpn J Antibiot. 1985 Apr;38(4):954-65.
We made fundamental and clinical studies of a new cephalosporin derivative cefpimizole (AC-1370), and found the following. In 7 patients treated with AC-1370 for the fundamental study of the drug, the blood level of the drug in the uterine artery scarcely differed from that in the elbow vein, and it decreased steadily with time. It remained to be 6.5 approximately 7.0 micrograms/ml 5 hours after intravenous injection of 1 g of the drug. The tissue-serum concentration ratio of the drug was 122 approximately 58% in the portio vaginalis where the drug was transferred at the highest level, and 56 approximately 114% in the oviduct where it was transferred at the lowest level; the mean level was 61.5%. The responses to AC-1370 of 10 patients with genital infections were excellent in 1, good in 8 and poor in the other, with a response rate of 90%. Bacteriologically, pathogens were eradicated in 3, decreased in 2, and the response was unknown in the other 5. No side effects or abnormal laboratory findings were noted except for leukopenia in 1 patient.
我们对新型头孢菌素衍生物头孢米诺（AC-1370）进行了基础和临床研究，结果如下。在7例接受AC-1370进行药物基础研究的患者中，子宫动脉中的药物血药浓度与肘静脉中的血药浓度几乎没有差异，且随时间稳步下降。静脉注射1g药物5小时后，血药浓度仍约为6.5至7.0微克/毫升。药物在阴道部的组织-血清浓度比最高，为122至58%，在输卵管中最低，为56至114%；平均水平为61.5%。10例生殖器感染患者对AC-1370的反应，1例为优，8例为良，1例为差，有效率为90%。细菌学方面，3例病原体被根除，2例减少，另外5例反应情况不明。除1例患者出现白细胞减少外，未观察到副作用或实验室检查异常结果。
